Exact Mass: 307.1339
Exact Mass Matches: 307.1339
Found 114 metabolites which its exact mass value is equals to given mass value 307.1339,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
5-Amino-2,3-dihydro-6-(3-hydroxy-4-methoxy-1-oxobutyl)-2,2-dimethyl-4H-1-benzopyran-4-one
5-Amino-2,3-dihydro-6-(3-hydroxy-4-methoxy-1-oxobutyl)-2,2-dimethyl-4H-1-benzopyran-4-one
5-Amino-2,3-dihydro-6-(3-hydroxy-4-methoxy-1-oxobutyl)-2,2-dimethyl-4H-1-benzopyran-4-one is isolated from rice cultures of Fusarium equiseti. Isolated from rice cultures of Fusarium equiseti
1,N2-propanodeoxyguanosine
3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H,4H,6H,7H,8H,10H-pyrimido[1,2-a]purin-10-one
1,N2-propanodeoxyguanosine belongs to the family of Purine 2-deoxyribonucleosides and Analogues. These are compounds consisting of a purine linked to a ribose which lacks an hydroxyl group at position 2.
6-(7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2-naphthamide
6-{7-hydroxy-5H,6H,7H-pyrrolo[1,2-c]imidazol-7-yl}-N-methylnaphthalene-2-carboxamide
Fabomotizole
5-ethoxy-2-{[2-(morpholin-4-yl)ethyl]sulfanyl}-1H-1,3-benzodiazole
C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent N - Nervous system > N05 - Psycholeptics > N05B - Anxiolytics
LY2183240
5-Biphenyl-4-ylmethyl-tetrazole-1-carboxylic acid dimethylamide
LY2183240 is a highly potent blocker of anandamide uptake (IC50= 270 pM; Ki=540 nM). LY2183240 is a potent, covalent inhibitor of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) with an IC50 of 12.4 nM. LY2183240 inactivates FAAH by carbamylation of the enzyme's serine nucleophile. LY2183240 also inhibits several other brain serine hydrolases with IC50s of 5.3, 0.09, 8.2 nM for MAG lipase, bh6 and KIAA1363, respectively[1][2] [3].
2-Cyclohex-3-enyl-6-[(3-methoxypropyl)amino]-4-oxo-3,4-dihydro-2H-1,3-thiazine-5-carbonitrile
2-Cyclohex-3-enyl-6-[(3-methoxypropyl)amino]-4-oxo-3,4-dihydro-2H-1,3-thiazine-5-carbonitrile
N4-[5-(2-Phenyleth-1-ynyl)-3-pyridyl]morpholine-4-carboxamide
N4-[5-(2-Phenyleth-1-ynyl)-3-pyridyl]morpholine-4-carboxamide
Foliosidine
Foliosidine
Origin: Plant; SubCategory_DNP: Alkaloids derived from anthranilic acid, Quinoline alkaloids, Foliosidine alkaloids relative retention time with respect to 9-anthracene Carboxylic Acid is 0.994 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.993 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.992 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.990
Me glycoside,N-Ac,4,6-O-benzylidene-alpha-D-Pyranose-2-Amino-2,3-dideoxy-ribo-hexopyranose
Me glycoside,N-Ac,4,6-O-benzylidene-alpha-D-Pyranose-2-Amino-2,3-dideoxy-ribo-hexopyranose
3-Deoxy-3-methylaminoxylose-1,2-O-Isopropylidene, N-benzoyl
3-Deoxy-3-methylaminoxylose-1,2-O-Isopropylidene, N-benzoyl
Apoatropine HCl
8-Methyl-8-azabicyclo[3.2.1]octan-3-yl 2-phenylprop-2-enoate--hydrogen chloride (1/1)
N-Allyladenosine
2-(6-Allylamino-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
relative retention time with respect to 9-anthracene Carboxylic Acid is 0.520 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.523 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.516 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.518
(Methoxymethyl)triphenylphosphonium
(Methoxymethyl)triphenylphosphonium
CONFIDENCE standard compound; INTERNAL_ID 2485
5-Amino-2,3-dihydro-6-(3-hydroxy-4-methoxybutanoyl)-2,2-dimethyl-4H-4-chromanone
5-Amino-2,3-dihydro-6-(3-hydroxy-4-methoxy-1-oxobutyl)-2,2-dimethyl-4H-1-benzopyran-4-one
(2S,4R)-1-(TERT-BUTOXYCARBONYL)-4-HYDROXY-3,3-DIMETHYLPYRROLIDINE-2-CARBOXYLICACID
(2S,4R)-1-(TERT-BUTOXYCARBONYL)-4-HYDROXY-3,3-DIMETHYLPYRROLIDINE-2-CARBOXYLICACID
N-[(3aS,4R,6S,6aR)-Tetrahydro-6-hydroxy-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]carbamicacid phenylmethyl ester
N-[(3aS,4R,6S,6aR)-Tetrahydro-6-hydroxy-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]carbamicacid phenylmethyl ester
ethyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-oxo-3-phenylpropanoate
ethyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-oxo-3-phenylpropanoate
((3AR,4R,6R,6AR)-6-(6-AMINO-9H-PURIN-9-YL)-2,2-DIMETHYLTETRAHYDROFURO[3,4-D][1,3]DIOXOL-4-YL)METHANOL
((3AR,4R,6R,6AR)-6-(6-AMINO-9H-PURIN-9-YL)-2,2-DIMETHYLTETRAHYDROFURO[3,4-D][1,3]DIOXOL-4-YL)METHANOL
2-((tert-Butyldimethylsilyloxy)methyl)furo[3,2-b]pyridine-6-carboxylic acid
2-((tert-Butyldimethylsilyloxy)methyl)furo[3,2-b]pyridine-6-carboxylic acid
ETHYL1-PHENYL-5-PHENYLAMINOIMIDAZOLE-4-CARBOXYLATE
ETHYL1-PHENYL-5-PHENYLAMINOIMIDAZOLE-4-CARBOXYLATE
ethyl 5-amino-1,4-diphenyl-1H-pyrazole-3-carboxylate
ethyl 5-amino-1,4-diphenyl-1H-pyrazole-3-carboxylate
6-Fluoro-1-methyl-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid
6-Fluoro-1-methyl-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid
6-methoxy-2-[(2-methylpropan-2-yl)oxycarbonyl]-3,4-dihydro-1H-isoquinoline-1-carboxylic acid
6-methoxy-2-[(2-methylpropan-2-yl)oxycarbonyl]-3,4-dihydro-1H-isoquinoline-1-carboxylic acid
2,3-O-Isopropylideneadenosine
2,3-O-Isopropylideneadenosine
2',3'-O-Isopropylideneadenosine is an adenosine analog. Adenosine analogs mostly act as smooth muscle vasodilators and have also been shown to inhibit cancer progression. Its popular products are adenosine phosphate, Acadesine (HY-13417), Clofarabine (HY-A0005), Fludarabine phosphate (HY-B0028) and Vidarabine (HY-B0277)[1].
(R)-Ethyl piperidine-3-carboxylate (2R,3R)-2,3-dihydroxysuccinate
(R)-Ethyl piperidine-3-carboxylate (2R,3R)-2,3-dihydroxysuccinate
(4-cyano-3,5-difluorophenyl) 4-propylcyclohexane-1-carboxylate
(4-cyano-3,5-difluorophenyl) 4-propylcyclohexane-1-carboxylate
3-(4-nitrophenoxycarbonyl)-2,2,5,5-tetramethyl-1-pyrrolidinyloxy
3-(4-nitrophenoxycarbonyl)-2,2,5,5-tetramethyl-1-pyrrolidinyloxy
3-(3-4-FLUOROPHENYL-1-ISOPROPYL-1H-INDOLE-2-YL) PROPENAL
3-(3-4-FLUOROPHENYL-1-ISOPROPYL-1H-INDOLE-2-YL) PROPENAL
N-(2,4,6-TRIMETHYLPHENYLCARBAMOYLMETHYL)IMINO-DIACETIC ACID,
N-(2,4,6-TRIMETHYLPHENYLCARBAMOYLMETHYL)IMINO-DIACETIC ACID,
1-[4-(2-chloroethoxy)phenyl]-3,3,4,4,4-pentadeuterio-2-phenylbutan-1-one
1-[4-(2-chloroethoxy)phenyl]-3,3,4,4,4-pentadeuterio-2-phenylbutan-1-one
2-methyl-N-(2,5,8,11-tetraoxabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl)-2-propenamide
2-methyl-N-(2,5,8,11-tetraoxabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl)-2-propenamide
4-{(2E)-2-[(1,2-dimethyl-1H-indol-3-yl)methylidene]hydrazinyl}benzoic acid
4-{(2E)-2-[(1,2-dimethyl-1H-indol-3-yl)methylidene]hydrazinyl}benzoic acid
4-(2,6-Dimethylphenoxy)-5-methoxy-2-(2-pyridinyl)pyrimidine
4-(2,6-Dimethylphenoxy)-5-methoxy-2-(2-pyridinyl)pyrimidine
2-Amino-N,N-Bis(Phenylmethyl)-1,3-Oxazole-5-Carboxamide
2-Amino-N,N-Bis(Phenylmethyl)-1,3-Oxazole-5-Carboxamide
Fabomotizole
Fabomotizole
C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent N - Nervous system > N05 - Psycholeptics > N05B - Anxiolytics
(1R,5S)-8-hydroxy-8-azabicyclo[3.2.1]oct-3-yl 3,4-dimethoxybenzoate
(1R,5S)-8-hydroxy-8-azabicyclo[3.2.1]oct-3-yl 3,4-dimethoxybenzoate
1-[[(2S)-2-[(2-aminoacetyl)amino]-4-methylpentanoyl]amino]ethenyl-methoxyphosphinic acid
1-[[(2S)-2-[(2-aminoacetyl)amino]-4-methylpentanoyl]amino]ethenyl-methoxyphosphinic acid
3-[(6-Methyl-4-phenyl-2-quinazolinyl)amino]propanoic acid
3-[(6-Methyl-4-phenyl-2-quinazolinyl)amino]propanoic acid
N-[2-(4-methoxyphenyl)ethyl]-2-quinoxalinecarboxamide
N-[2-(4-methoxyphenyl)ethyl]-2-quinoxalinecarboxamide
N-[[(1-oxo-3-phenylpropyl)hydrazo]-sulfanylidenemethyl]pentanamide
N-[[(1-oxo-3-phenylpropyl)hydrazo]-sulfanylidenemethyl]pentanamide
2-(4-methyl-1-oxo-2-phthalazinyl)-N-(4-methylphenyl)acetamide
2-(4-methyl-1-oxo-2-phthalazinyl)-N-(4-methylphenyl)acetamide
1-(4-tert-butylphenoxy)-3-(1H-1,2,4-triazol-5-ylthio)-2-propanol
1-(4-tert-butylphenoxy)-3-(1H-1,2,4-triazol-5-ylthio)-2-propanol
1,4-Dioxa-8-azaspiro[4.5]decan-8-yl(4,5,6,7-tetrahydro-1-benzothiophen-2-yl)methanone
1,4-Dioxa-8-azaspiro[4.5]decan-8-yl(4,5,6,7-tetrahydro-1-benzothiophen-2-yl)methanone
N-(5-methyl-2-phenyl-3-pyrazolyl)-2-phenoxyacetamide
N-(5-methyl-2-phenyl-3-pyrazolyl)-2-phenoxyacetamide
2-(4-(5,5-Dimethyl-1,3,2-dioxaborinan-2-yl)phenyl)benzo[d]oxazole
2-(4-(5,5-Dimethyl-1,3,2-dioxaborinan-2-yl)phenyl)benzo[d]oxazole
2-[(2S,5S,6S)-5-benzamido-6-(hydroxymethyl)-2-oxanyl]acetic acid methyl ester
2-[(2S,5S,6S)-5-benzamido-6-(hydroxymethyl)-2-oxanyl]acetic acid methyl ester
2-[(1R,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]acetic acid
2-[(1R,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]acetic acid
2-[(1S,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
2-[(1S,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
2-[(1S,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]acetic acid
2-[(1S,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]acetic acid
2-[(2R,5R,6S)-5-benzamido-6-(hydroxymethyl)-2-oxanyl]acetic acid methyl ester
2-[(2R,5R,6S)-5-benzamido-6-(hydroxymethyl)-2-oxanyl]acetic acid methyl ester
2-[(2R,5R,6R)-5-benzamido-6-(hydroxymethyl)-2-oxanyl]acetic acid methyl ester
2-[(2R,5R,6R)-5-benzamido-6-(hydroxymethyl)-2-oxanyl]acetic acid methyl ester
2-[(2S,5R,6R)-5-benzamido-6-(hydroxymethyl)-2-oxanyl]acetic acid methyl ester
2-[(2S,5R,6R)-5-benzamido-6-(hydroxymethyl)-2-oxanyl]acetic acid methyl ester
2-[(1R,3R,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
2-[(1R,3R,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
2-[(2S,5R,6S)-5-benzamido-6-(hydroxymethyl)-2-oxanyl]acetic acid methyl ester
2-[(2S,5R,6S)-5-benzamido-6-(hydroxymethyl)-2-oxanyl]acetic acid methyl ester
2-[(2R,5S,6R)-5-benzamido-6-(hydroxymethyl)-2-oxanyl]acetic acid methyl ester
2-[(2R,5S,6R)-5-benzamido-6-(hydroxymethyl)-2-oxanyl]acetic acid methyl ester
2-[(2S,5S,6R)-5-benzamido-6-(hydroxymethyl)-2-oxanyl]acetic acid methyl ester
2-[(2S,5S,6R)-5-benzamido-6-(hydroxymethyl)-2-oxanyl]acetic acid methyl ester
2-[(2R,5S,6S)-5-benzamido-6-(hydroxymethyl)-2-oxanyl]acetic acid methyl ester
2-[(2R,5S,6S)-5-benzamido-6-(hydroxymethyl)-2-oxanyl]acetic acid methyl ester
2-[(1S,3R,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
2-[(1S,3R,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid
2-amino-7-[4-hydroxy-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-(methylaminomethyl)-3H-pyrrolo[2,3-d]pyrimidin-4-one
2-amino-7-[4-hydroxy-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-(methylaminomethyl)-3H-pyrrolo[2,3-d]pyrimidin-4-one
5-Amino-2,3-dihydro-6-(3-hydroxy-4-methoxy-1-oxobutyl)-2,2-dimethyl-4H-1-benzopyran-4-one
5-Amino-2,3-dihydro-6-(3-hydroxy-4-methoxy-1-oxobutyl)-2,2-dimethyl-4H-1-benzopyran-4-one
1A-116
1A-116
1A-116, a potent Rac1 inhibitor, is specific for W56 residues, can prevent EGF-induced Rac1 activation and block Rac1-P-Rex1 interaction. 1A-116 can induce apoptosis and inhibit cell proliferation, migration and cycle progression in a concentration-dependent manner. 1A-116 also demonstrates a high antimetastatic activity in vivo[1][2][3].
FAAH/MAGL-IN-5
FAAH/MAGL-IN-5
AM6701 is a potent FAAH/MAGL inhibitor (equipotent inhibitory IC50: 1.2 nM) with neuroprotective effects[1].
2-hydroxy-n-[(1s)-1-[(3s)-8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl]-3-methylbutyl]ethanimidic acid
2-hydroxy-n-[(1s)-1-[(3s)-8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl]-3-methylbutyl]ethanimidic acid
(1r,7ar)-7-({[(2z)-3-hydroxyprop-2-enoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2e)-2-methylbut-2-enoate
(1r,7ar)-7-({[(2z)-3-hydroxyprop-2-enoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2e)-2-methylbut-2-enoate
10-{[2-(4-hydroxyphenyl)ethyl]amino}-2,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-1(12),3,7,9-tetraen-11-one
10-{[2-(4-hydroxyphenyl)ethyl]amino}-2,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-1(12),3,7,9-tetraen-11-one
methyl (5e)-3-[(4-formylphenyl)amino]-4,7-dihydroxyoct-5-enoate
methyl (5e)-3-[(4-formylphenyl)amino]-4,7-dihydroxyoct-5-enoate
2-hydroxy-n-[1-(8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl)-3-methylbutyl]ethanimidic acid
2-hydroxy-n-[1-(8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl)-3-methylbutyl]ethanimidic acid
10-{[2-(4-hydroxyphenyl)ethyl]amino}-2,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-1,3,8(12),9-tetraen-11-one
10-{[2-(4-hydroxyphenyl)ethyl]amino}-2,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-1,3,8(12),9-tetraen-11-one
methyl 3-[(4-formylphenyl)amino]-4,7-dihydroxyoct-5-enoate
methyl 3-[(4-formylphenyl)amino]-4,7-dihydroxyoct-5-enoate
(16s)-16-hydroxy-4,14,19-triazatetracyclo[15.3.1.0³,¹¹.0⁵,¹⁰]henicosa-1(20),3(11),5,7,9,17(21),18-heptaen-2-one
(16s)-16-hydroxy-4,14,19-triazatetracyclo[15.3.1.0³,¹¹.0⁵,¹⁰]henicosa-1(20),3(11),5,7,9,17(21),18-heptaen-2-one
(1r,3s,5s)-8-hydroxy-8-azabicyclo[3.2.1]octan-3-yl 3,4-dimethoxybenzoate
(1r,3s,5s)-8-hydroxy-8-azabicyclo[3.2.1]octan-3-yl 3,4-dimethoxybenzoate
(15r,19r,20s)-19-hydroxy-3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2(10),4,6,8,11-hexaen-14-one
(15r,19r,20s)-19-hydroxy-3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2(10),4,6,8,11-hexaen-14-one
8-(2,3-dihydroxy-3-methylbutoxy)-4-methoxy-1-methylquinolin-2-one
8-(2,3-dihydroxy-3-methylbutoxy)-4-methoxy-1-methylquinolin-2-one
(1r,3r,5s,6s,7r)-6,7-dihydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 2-(3-hydroxyphenyl)acetate
(1r,3r,5s,6s,7r)-6,7-dihydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 2-(3-hydroxyphenyl)acetate
(2s)-2-{[(2r)-2-amino-1-hydroxypropylidene]amino}-4-(6-aminopurin-9-yl)butanoic acid
(2s)-2-{[(2r)-2-amino-1-hydroxypropylidene]amino}-4-(6-aminopurin-9-yl)butanoic acid
10-{[2-(4-hydroxyphenyl)ethyl]amino}-2,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-1(11),2,4(12),7,9-pentaen-11-ol
10-{[2-(4-hydroxyphenyl)ethyl]amino}-2,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-1(11),2,4(12),7,9-pentaen-11-ol
4-methoxy-1-methyl-3-(2,3,4-trihydroxy-3-methylbutyl)quinolin-2-one
4-methoxy-1-methyl-3-(2,3,4-trihydroxy-3-methylbutyl)quinolin-2-one
16-hydroxy-4,14,19-triazatetracyclo[15.3.1.0³,¹¹.0⁵,¹⁰]henicosa-1(20),3(11),5,7,9,17(21),18-heptaen-2-one
16-hydroxy-4,14,19-triazatetracyclo[15.3.1.0³,¹¹.0⁵,¹⁰]henicosa-1(20),3(11),5,7,9,17(21),18-heptaen-2-one
19-hydroxy-3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2(10),4,6,8,11-hexaen-14-one
19-hydroxy-3,13,21-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-1(21),2(10),4,6,8,11-hexaen-14-one
